Additional Information

Description

Firmagon (Degarelix) 80 mg vial is a medication used in the treatment of prostate cancer. It contains the active ingredient degarelix, a selective GnRH receptor antagonist. By blocking the action of gonadotropin-releasing hormone (GnRH), degarelix reduces the production of testosterone, which is a key driver of prostate cancer cell growth. This action helps in lowering testosterone levels to castration levels, effectively inhibiting tumor growth in patients with advanced prostate cancer.

The drug is administered via subcutaneous injection, typically in two doses of 240 mg each, followed by maintenance doses of 80 mg every 28 days. The dosage and treatment plan may vary depending on the patient's response and medical condition. Firmagon is used in patients with advanced prostate cancer to manage symptoms and slow disease progression.

Common side effects of Firmagon include hot flashes, fatigue, injection site reactions, and elevated liver enzymes. Serious side effects, though rare, may include allergic reactions, heart-related issues, or changes in bone mineral density. Close monitoring of liver function and cardiovascular health is recommended during treatment.